Loading clinical trials...
Loading clinical trials...
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-naïve Subjects With Primary Immunodeficiency
Conditions
Interventions
IgPro
Locations
8
United States
Research Solutions of AZ
Litchfield Park, Arizona, United States
Medical Research of Arizona
Scottsdale, Arizona, United States
Immunoe Health Centers
Centennial, Colorado, United States
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Midwest Immunology
Plymouth, Minnesota, United States
Washington University
St Louis, Missouri, United States
Start Date
July 15, 2025
Primary Completion Date
June 30, 2026
Completion Date
June 30, 2026
Last Updated
April 22, 2026
NCT03610802
NCT03394053
NCT07346859
NCT04902807
NCT04944979
NCT05236764
Lead Sponsor
CSL Behring
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions